A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 (LOTUS)

被引：0
|
作者：
Pouchain, Denis [1 ]
Boussageon, Remy [1 ,2 ,3 ]
Leroux, Gerard [4 ]
机构：
[1] CNGE, Conseil Sci, Paris, France
[2] Univ Claude Bernard Lyon 1, Coll Univ Med Gen, Lyon, France
[3] Fac RTH Laennec, Lab Biometrie & Biol Evolut, UMR 5558, Lyon, France
[4] Univ Paris Est Creteil, Dept Med Gen, Paris, France
来源：
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE | 2020年 / 162期
关键词：
IN-VITRO; SARS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：172 / 173
页数：2
相关论文
共 50 条
  • [41] Remdesivir versus ritonavir/lopinavir in COVID-19 patients
    Antonio Vitiello
    Francesco Ferrara
    Irish Journal of Medical Science (1971 -), 2021, 190 : 1249 - 1250
  • [42] Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
    Reactions Weekly, 2020, 1814 (1) : 9 - 9
  • [43] Remdesivir versus ritonavir/lopinavir in COVID-19 patients
    Vitiello, Antonio
    Ferrara, Francesco
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (03) : 1249 - 1250
  • [44] Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
    Alvarez, Jean Claude
    Moine, Pierre
    Davido, Benjamin
    Etting, Isabelle
    Annane, Djillali
    Larabi, Islam Amine
    Simon, Nicolas
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (03) : 389 - 397
  • [45] Lopinavir / ritonavir for COVID-19: A living systematic review
    Verdugo-Paiva, Francisca
    Izcovich, Ariel
    Ragusa, Martin
    Rada, Gabriel
    MEDWAVE, 2020, 20 (06):
  • [46] Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
    Jean Claude Alvarez
    Pierre Moine
    Benjamin Davido
    Isabelle Etting
    Djillali Annane
    Islam Amine Larabi
    Nicolas Simon
    European Journal of Clinical Pharmacology, 2021, 77 : 389 - 397
  • [47] Letter to the Editor: Pharmacokinetics of Lopinavir/Ritonavir in Hospitalized Patients with COVID-19 Not Requiring Critical Care
    MacGowan, Alasdair
    Hamilton, Fergus
    Bayliss, Mark
    Read, Liam
    Attwood, Marie
    Noel, Alan
    Albur, Maha
    Grier, Sally
    Morley, Anna
    Arnold, David
    Maskell, Nicholas
    MICROBIAL DRUG RESISTANCE, 2022, 28 (05) : 611 - 612
  • [48] Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19
    Klement-Frutos, Elise
    Burrel, Sonia
    Peytavin, Gilles
    Marot, Stephane
    Le, Minh P.
    Godefroy, Nagisa
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    Caumes, Eric
    Pourcher, Valerie
    Boutolleau, David
    JOURNAL OF INFECTION, 2021, 82 (01) : 194 - 197
  • [49] An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results
    Ader, Florence
    CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (09) : 1293 - 1296
  • [50] Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients
    Baghaei, Parvaneh
    Dastan, Farzaneh
    Marjani, Majid
    Moniri, Afshin
    Abtahian, Zahra
    Ghadimi, Somayeh
    Valizadeh, Melika
    Heshmatnia, Jalal
    Mirenayat, Maryam Sadat
    Abedini, Atefeh
    Kiani, Arda
    Eslaminejad, Alireza
    Hashemian, Seyed MohammadReza
    Jamaati, Hamidreza
    Zali, Alireza
    Velayati, Ali Akbar
    Tabarsi, Payam
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 92
12345